Core Viewpoint - The company, Yidu Tech (02158), demonstrates confidence in its development and industry prospects through continuous share buybacks and product innovation in the AI healthcare sector [1]. Group 1: Share Buyback Activity - On February 24, Yidu Tech announced a share buyback of 720,000 shares at approximately HKD 5.96 per share, totaling nearly HKD 4.3 million [1]. - Since January 26, the company has completed 17 buybacks, with a cumulative expenditure exceeding HKD 72 million, reflecting a strong commitment to shareholder value [1]. Group 2: Product Development - Yidu Tech's clinical evidence-based AI tool, "Yidu Zhixun," has entered internal testing, aimed at clinical doctors and medical researchers, focusing on real-world clinical and research needs [1]. - The internal testing involves frontline doctors with real practice backgrounds to optimize the product's clinical usability based on actual feedback [1]. - The previously developed "Doctor Copilot" tool has been utilized nearly 1,000 times daily in a single hospital, covering about 70% of clinical healthcare personnel, indicating strong product adoption [1]. Group 3: Industry Context - The AI healthcare industry is driven by both policy and technology, with a joint issuance from eight national departments outlining plans for full coverage of intelligent diagnostic assistance in secondary hospitals by 2030 [1]. - Clinical evidence-based tools are becoming essential in the industry, positioning Yidu Tech favorably as it continues to innovate and reinforce its competitive edge in the AI healthcare sector [1].
医渡科技1个月内回购17次 临床循证智能体“医渡智循”已开启内测